Cargando…
Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T‐cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Un...
Autores principales: | Kuiper, Roland P., Hoogeveen, Patricia G., Bladergroen, Reno, van Dijk, Freerk, Sonneveld, Edwin, van Leeuwen, Frank N., Boer, Judith, Sergeeva, Irina, Feitsma, Harma, den Boer, Monique L., van der Velden, Vincent H. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291030/ https://www.ncbi.nlm.nih.gov/pubmed/34337744 http://dx.doi.org/10.1111/bjh.17744 |
Ejemplares similares
-
ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023) -
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
por: Jones, Jeffrey, et al.
Publicado: (2018) -
Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia
por: Bras, Anne E., et al.
Publicado: (2020) -
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016) -
Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study
por: Verbeek, Martijn W. C., et al.
Publicado: (2021)